GlassScriptPhysician profile
Sean Connor Curran
NPI 1699709071
$6,419.08
in general payments reported to CMS, 2019-2025
28 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $248 · 2021: $1,116 · 2022: $1,454 · 2023: $940 · 2024: $875 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,724.17 | 2019-2025 | |
| Pfizer INC. | $999.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $807.10 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $409.81 | 2019-2024 | Watchman, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $300.05 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $285.52 | 2021-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $226.92 | 2021-2024 | Verquvo |
| Impulse Dynamics (USA) INC. | $207.49 | 2022-2025 | Optimizer |
| Amgen INC. | $205.22 | 2019-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $177.25 | 2024-2025 | |
| Novo Nordisk INC | $127.41 | 2024-2025 | Wegovy |
| Daiichi Sankyo INC. | $125.87 | 2024-2025 | Injectafer |
| Amarin Pharma, INC. | $124.85 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $106.60 | 2022-2025 | Onpattro, Amvuttra |
| Abiomed | $83.41 | 2024-2025 | Impella |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $82.79 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $78.44 | 2023 | Arcalyst |
| Heartflow, INC. | $62.46 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.84 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $40.75 | 2019-2022 | |
| Atricure, INC. | $37.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.20 | 2022-2023 | |
| Abbott Laboratories | $24.42 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Regeneron Healthcare Solutions, INC. | $23.53 | 2019 | |
| Preventice Services, LLC | $22.86 | 2020 | |
| Inspire Medical Systems, INC. | $19.14 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.89 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $15.44 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Curran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.